New doxorubicin nanocarriers based on cyclodextrins Maurizio VialeValentina GiglioGraziella Vecchio PRECLINICAL STUDIES 04 April 2017 Pages: 539 - 544
Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation Magdalena OlbrytAleksandra RusinWaldemar Priebe PRECLINICAL STUDIES Open access 17 April 2017 Pages: 545 - 555
Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia Masamichi MoriNaoki KanekoSadao Kuromitsu PRECLINICAL STUDIES Open access 17 May 2017 Pages: 556 - 565
Decorin gene upregulation mediated by an adeno-associated virus vector increases intratumoral uptake of nab-paclitaxel in neuroblastoma via inhibition of stabilin-1 Zijun ZhenKaibin YangYing Liu PRECLINICAL STUDIES 20 June 2017 Pages: 566 - 575
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors Jeffrey R. InfanteRoger B. CohenPatricia M. LoRusso PHASE I STUDIES Open access 19 April 2017 Pages: 576 - 588
Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer L. van AndelS. FudioJ. H. Beijnen PHASE I STUDIES 23 January 2017 Pages: 589 - 598
ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer Simon J. CrabbAlison J. BirtleRobert J. Jones PHASE I STUDIES Open access 01 February 2017 Pages: 599 - 607
Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553) Susanne M. ArnoldKari ChanskyMaria Q. Baggstrom PHASE I STUDIES Open access 16 February 2017 Pages: 608 - 615
Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors Monica MitaSiqing FuAung Naing PHASE I STUDIES 13 February 2017 Pages: 616 - 626
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers Jennifer R. DiamondBarbara GoffKathleen M. Moore PHASE I STUDIES 10 March 2017 Pages: 627 - 633
A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C Khaldoun AlmhannaDavid WrightThea Kalebic PHASE II STUDIES 19 May 2017 Pages: 634 - 641
Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer Satoshi IgawaSakiko OtaniNoriyuki Masuda PHASE II STUDIES 20 June 2017 Pages: 642 - 648
Resistance to immunotherapy: clouds in a bright sky Gérard Milano REVIEW 12 April 2017 Pages: 649 - 654
Gankyrin as a potential therapeutic target for cancer Chongchong WangLi Cheng REVIEW 19 May 2017 Pages: 655 - 661
Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexed Goushi MatamaTakaaki TokitoTomoaki Hoshino SHORT REPORT 30 March 2017 Pages: 662 - 664
Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence Diego A. Adrianzen HerreraSarah B. FleisigBenjamin A. Gartrell SHORT REPORT 02 May 2017 Pages: 665 - 668
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors Jeffrey R. InfanteRoger B. CohenPatricia M. LoRusso Erratum Open access 05 July 2017 Pages: 669 - 669
